The Latest Breaking News from FDA

Donald Trump plans to skip testifying for a second time in the New York civil fraud trial. The FDA has approved the first-ever gene-editing treatment for a human disease.

Ministers are spending £290m of taxpayers’ money on a scheme that is yet to deliver. It’s our job as public servants to point out flaws in their plans, says Dave Penman, general secretary of the FDA union

The announcement comes after the FDA became aware of more than 40 cases of "DRESS syndrome" linked to the seizure medications levetiracetam and clobazam.

The Food and Drug Administration approved two genetic treatments for sickle cell disease, including one that uses gene-editing. The approvals offer hope for patients and signal a new medical era.

Big money brings tough competition, and businesses can try all sorts of tactics to get an edge. The post “No Such Thing As Organic Honey”: 50 People Share Food Industry Secrets first appeared on Bored Panda.

House lawmakers are demanding information on federal efforts to stop the influx of kid-appealing electronic cigarettes from China

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

A Kentucky child is dead and a Missouri infant has brain damage from the same kind of bacteria that sparked powdered formula recalls and shortages last year

The pharmaceutical sector is transforming due to the swift uptake of digital solutions and worldwide spending growth. Hence, fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Astellas Pharma (ALPMY), and Eli Lilly (LLY) might be solid buys now. Read more….